Research

*January 2025* The FDA has accepted and granted priority review to the biologics license application (BLA) for datopotamab deruxtecan (Dato-DXd). This investigational treatment is intended for adults with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who have previously received systemic therapies, including EGFR-targeted treatments. The FDA’s decision…

*May 2025* Highlights •Patients with EGFR-mutated NSCLC that progresses after osimertinib treatment need additional treatment options. •c-Met protein expression correlates with osimertinib resistance. •Teliso-V is an antibody–drug conjugate that targets c-Met protein overexpression. •Teliso-V + osimertinib had promising activity in EGFR-mut, c-Met protein-overexpressing NSCLC post-osimertinib progression. •The combination of Teliso-V…

*February 2025* In this video, Mara B. Antonoff, MD, FACS, of the University of Texas MD Anderson Cancer Center, joined Lung Cancers Today to discuss a session on operating in stage IV lung cancer held at the 61st Annual Meeting of the Society of Thoracic Surgeons (STS) in Los Angeles.…

*February 2025* In this video, Stephen Liu, MD, of the Georgetown University School of Medicine and Georgetown's Lombardi Comprehensive Cancer Center in Washington, DC, joined Lung Cancers Today to discuss the recent announcement that the phase 3 MARIPOSA trial met its final pre-specified secondary endpoint of overall survival (OS). The…

*November 2024* In this video, Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, discuss the next steps for biomarker testing in NSCLC. Watch here.  

*November 2024* Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie, discusses de novo vs acquired resistance alterations in HER2-positive non–small cell lung cancer (NSCLC). In HER2-positive NSCLC, alterations can be broadly categorized as either de novo mutations or acquired resistance mutations, Girard begins. De novo mutations…

*November 2024* Key Takeaways Datopotamab deruxtecan targets EGFR-mutated advanced NSCLC, showing promising response and disease control rates in the TROPION-Lung05 trial. The TROPION-Lung01 trial showed non-significant overall survival improvement, leading to the withdrawal of the BLA for nonsquamous NSCLC. Safety data indicated that all patients experienced treatment-emergent adverse effects, with…